Recent advances in therapeutic applications of human peptide transporters

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 2, 2005, Pages 153-166

  Nielsen, Carsten Uhd ^a   Våbenø, Jon ^a,b   Andersen, Rikke ^a   Brodin, Birger ^a   Steffansen, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Genetic variation; hPEPT1; hPEPT2; Molecular modelling; Peptide transporter; SLC15A1; SLC15A2; Substrate recognition; Valaciclovir; Valganciclovir

Indexed keywords

ACICLOVIR; ALAFOSFALIN; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBONYL DERIVATIVE; CEFALEXIN; CYSTEINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EUDRAGIT; GABAPENTIN; GANCICLOVIR; LACTOSE PERMEASE; NEW DRUG; PEPTIDE TRANSPORTER 1; POLYMER; THIAZOLE DERIVATIVE; VALACICLOVIR;

BINDING AFFINITY; COMPUTER ANALYSIS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EXCRETION; DRUG FORMULATION; DRUG RESEARCH; DRUG STRUCTURE; ELECTRICITY; EYE INFECTION; GENETIC VARIABILITY; HUMAN; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; MUTAGENESIS; NONHUMAN; PH; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOPHORE; POPULATION GENETICS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS;

EID: 14544273652     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.2.153     Document Type: Review

References (81)

1. NIELSEN CU, BRODIN B, JORGENSEN FS, FROKJAER S, STEFFANSEN B: Human peptide transporters: therapeutic applications. Expert Opin. Ther. Patents (2002) 12:1329-1350.
2. +/peptide cotransporter PEPT1. J. Med. Chem. (2003) 46:5725-5734.
3. LI J, HIDALGO IJ: Molecular modeling study of structural requirements for the oligopeptide transporter. J. Drug Target. (1996) 4:9-17.
4. VÅBENØ J, NIELSEN CU, INGEBRIGTSEN T, LEJON T, STEFFANSEN B, LUTHMAN K: Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, biological investigations. J. Med. Chem. (2004) 47:4755-4765.
5. VÅBENØ J, LEJON T, NIELSEN CU et al.: Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: Synthesis and biological investigations. J. Med. Chem. (2004) 47:1060-1069.
6. NOZAWA T, TOYOBUKU H, KOBAYASH D, KURUMA K, TSUJI A, TAMAI I: Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. J. Pharm. Sci. (2003) 92:2208-2216.
7. ZHANG EY, FU DJ, PAK YA et al.: Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: Implications for the functional role of Pro586. J. Pharmacol. Exp. Ther. (2004) 310: 437-445.
8. +/dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. Exp. Ther. (2004) 311:1088-1096.
9. NIELSEN CU, BRODIN B: Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and patho-physiological conditions. Curr. Drug Targets (2003) 4 373-388.
10. DANIEL H: Molecular and integrative physiology of intestinal peptide transport. Ann. Rev. Physiol. (2004) 66:361-384.
11. TERADA T, INUI K: Peptide transporters: structure, function, regulation and application for drug delivery. Curr. Drug Metab. (2004) 5:85-94.
12. GRONEBERG DA, FISCHER A, CHUNG KF, DANIEL H: Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am. J. Resp. Cell Mol. (2004) 30:251-260.
13. DANIEL H, KOTTRA G: The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. (2004) 447:610-618.
14. +/peptide symporter PEPT1: structure-affinity relationships. Eur. J. Pharm. Sci. (2004) 21:53-60.
15. DANIEL H, RUBIO-ALIGA I: An update on renal peptide transporters. Am. J. Physiol. Renal Physiol. (2003) 284 F885-F892.
16. HERRERA-RUIZ D, KNIPP GT: Current perspectives on established and putative mammalian oligopeptide transporters. J. Pharm. Sci. (2003) 92:691-714.
17. DORING F, WALTER J, WILL J et al.: Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J. Clin. Invest. (1998) 101:2761-2767.
18. KNUTTER I, HARTRODT B, THEIS S et al.: Analysis of the transport properties of side chain modified dipeptides at the mammalian peptide transporter PEPT1. Eur. J. Pharm. Sci. (2004) 21 61-67.
19. KNUTTER I, THEIS S, HARTRODT B et al.: A novel inhibitor of the mammalian peptide transporter PEPT1. Biochemistry (2001) 40: 4454-4458.
20. DORING F, WILL J, AMASHEH S, CLAUSS W, AHLBRECHT H, DANIEL H: Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J. Biol. Chem. (1998) 273 23211-23218.
21. MEREDITH D, TEMPLE CS, GUHA N et al.: Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. Eur. J. Biochem. (2000) 267:3723-3728.
22. SWAAN PW, TUKKER JJ: Molecular determinants of recognition for the intestinal peptide carrier. J. Pharm. Sci. (1997) 86 596-602.
23. SWAAN PW, KOOPS BC, MORET EE, TUKKER JJ: Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis. Recept. Channels (1998) 6:189-200.
24. BAILEY PD, BOYD R, BRONK JR et al.: How to make drugs orally active: a substrate templete for peptide transporter PepT1. Angew. Chem. Int. Ed. (2000) 39:505-508.
25. NIELSEN CU, ANDERSEN R, BRODIN B, FROKJAER S, TAUB ME, STEFFANSEN B: Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity to and transport via hPepT1 in the human intestinal Caco-2 cell line. J. Control. Rel. (2001) 76:129-138.
26. VÅBENØ J, NIELSEN CU, STEFFANSEN B et al.: Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: Implications for design of hPEPT1 targeted prodrugs. Bioorg. Med. Chem. in press.
27. FARIA T, TIMOSZYK JK, STOUCH TR et al.: A novel high-troughput PepT1 transporter assay differentiates between substrates and antagonists. Mol. Pharm. (2004) 1:67-76.
28. COVITZ KMY, AMIDON GL, SADEE W: Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 37:15214-15221.
29. DORING F, MARTINI C, WALTER J, DANIEL H: Importance of a small N-terminal region in mammalian peptide transporters for substrate affinity and function. J. Membr. Biol. (2002) 186:55-62.
30. FEI YJ, LIU JC, FUJITA T, LIANG R, GANAPATHY V, LEIBACH FH: Identification of a potential substrate binding domain in the mammalian peptide transporters PEPT1 and PEPT2 using PEPT1-PEPT2 and PEPT2-PEPT1 chimeras. Biochem. Biophys. Res. Commun. (1998) 246:39-44.
31. +/peptide transporters are responsible for their substrate recognition. Pharm. Res. (2000) 17:15-20.
32. LEE VH, CHU C, MAHLIN ED et al.: Biopharmaceutics of transmucosal peptide and protein drug administration: role of transport mechanisms with a focus on the involvement of PepT1. J. Control Rel. (1999) 62:129-140.
33. YEUNG AK, BASU SK, WU SK et al.: Molecular identification of a role for tyrosine 167 in the function of the human intestinal proton- coupled dipeptide transporter (hPepT1). Biochem. Biophys. Res. Commun. (1998) 250: 103-107.
34. BOLGER MB, HAWORTH IS, YEUNG AK et al.: Structure, function, and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1. J. Pharm. Sci. (1998) 87 1286-1291.
35. +-peptide transporter PepT1. Biochem. Biophys. Res. Commun. (2000) 272:726-730.
36. FEI YJ, LIU W, PRASAD PD et al.: Identification of the histidyl residue obligatory for the catalytic activity of the human H+/peptide cotransporters PEPT1 and PEPT2. Biochemistry (1997) 36:452-460.
37. +/peptide cotransporter, PEPT1. FEBS Lett. (1996) 394:196-200.
38. KULKARNI AA, HAWORTH IS, LEE VH: Transmembrane segment 5 of the dipeptide transporter hPepT1 forms a part of the substrate translocation pathway. Biochem. Biophys. Res. Commun. (2003) 306 177-185.
39. KULKARNI AA, HAWORTH IS, UCHIYAMA T, LEE VH: Analysis of transmembrane segment 7 of the dipeptide transporter hPepT1 by cysteine-scanning mutagenesis. J. Biol. Chem. (2003) 278 51833-51840.
40. UCHIYAMA T, KULKARNI AA, DAVIES DL, LEE VH: Biophysical evidence for His57 as a proton-binding site in the mammalian intestinal transporter hPepT1. Pharm. Res. (2003) 20:1911-1916.
41. MEREDITH D: Site-directed mutation of arginine 282 to glutamate uncouples the movement of peptides and protons by the rabbit proton-peptide cotransporter PePT1. J. Biol. Chem. (2004) 279 15795-15798.
42. ABRAMSON J, SMIRNOVA I, KASHO V, VERNER G, IWATA S, KABACK HR: The lactose permease of Escherichia coli: overall structure, the sugar-binding site and the alternating access model for transport. FEBS Lett. (2003) 555:96-101.
43. BOLGER MB: Oligopeptide transporter (PepT1) homology model based on lactose permease (LacY). Abstracts of Papers, 227th ACS National Meeting: Anaheim, CA, USA (2004).
44. STOUCH TR, FARIA T, TIMOSZYK J. PepT1 substrate transport pharmacophore determinants: Refinement with data from a single consistent functional assay. Abstracts of Papers, 227th ACS National Meeting: Anaheim, CA, USA (2004).
45. FOLTZ M, MEYER A, THEIS S, DEMUTH HU, DANIEL H: A rapid in vitro screening for delivery of peptide-derived peptidase inhibitors as potential drug candidates via epithelial peptide transporters. J. Pharmacol. Exp. Ther. (2004) 310:695-702.
46. LANDOWSKI CP, SUN DX, FOSTER DR et al.: Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther. (2003) 306 778-786.
47. DANTZIG AH: Oral absorption of β-lactams by intestinal peptide transport proteins. Adv. Drug Deliv. Rev. (1998) 23 63-76.
48. MACDOUGALL C, GUGLIELMO BJ: Pharmacokinetics of valaciclovir. J. Antimicrob. Chemother. (2004) 53:899-901.
49. ANAND BS, PATEL J, MITRA AK: Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: Competitive inhibition of glycylsarcosine transport in human intestinal cell line Caco-2. J. Pharmacol. Exp. Ther. (2003) 304 781-791.
50. ANAND BS, KATRAGADDA S, MITRA AK: Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J. Pharmacol. Exp. Ther. (2004) 311:659-667.
51. SPINA E, PERUGI G: Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. (2004) 6:57-75.
52. ALLEN JG, HAVAS L, LEICHT E, LENOX-SMITH I, NISBET LJ: Phosphonopeptides as antibacterial agents: metabolism and pharmacokinetics of alafosfalin in animals and humans. Antimicrob. Agents Chemother. (1979) 16:306-313.
53. ALLEN JG, LEES LJ: Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans. Antimicrob. Agents Chemother. (1980) 17:973-979.
54. BERGAN T: Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives. Chemotherapy (1990) 36 1):10-18.
55. GRAPPEL SF, GIOVENELLA AJ, NISBET LJ: Activity of a peptidyl prodrug, alafosfalin, against anaerobic bacteria. Antimicrob. Agents Chemother. (1985) 27: 961-963.
56. ATHERTON FR, HALL MJ, HASSALL CH et al.: Phosphonopeptides as substrates for peptide transport systems and peptidases of Escherichia coli. Antimicrob. Agents Chemother. (1983) 24:522-528.
57. +/peptide cotransporters PEPT1 and PEPT2 in intestinal and renal epithelial cells. Eur. J. Biochem. (2004) 271:2012-2017.
58. BECONI MG, MAO A, LIU DQ et al.: Metabolism and pharmacokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs. Drug Metab. Dispos. (2003) 31:1269-1277.
59. ANAND BS, MITRA AK: Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res. (2002) 19:1194-1202.
60. ANAND B, NASHED Y, MITRA A: Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Curr. Eye Res. (2003) 26 151-163.
61. + and expression of the transporter in tissues amenable for drug delivery. J. Pharmacol. Exp. Ther. (2004) 308 1138-1147.
62. OCHELTREE SM, KEEP RF, SHEN H, YANG D, HUGHES BA, SMITH DE: Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes. Pharm. Res. (2003) 20:1364-1372.
63. ATLURI H, ANAND BS, PATEL J, MITRA AK: Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration. Exp. Eye Res. (2004) 78:815-822.
64. SHEN H, SMITH DE, KEEP RF, XIANG J, BROSIUS FC III: Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. J. Biol. Chem. (2003) 278:4786-4791.
65. TEUSCHER NS, SHEN H, SHU C, XIANG J, KEEP RF, SMITH DE: Carnosine uptake in rat choroid plexus primary cell cultures and choroid plexus whole tissue from PEPT2 null mice. J. Neurochem. (2004) 89:375-382.
66. OCHELTREE SM, SHEN H, HU Y, XIANG J, KEEP RF, SMITH DE: Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. J. Pharmacol. Exp. Ther. (2004) 308:462-467.
67. BERGER UV, HEDIGER MA: Distribution of peptide transporter PEPT2 mRNA in the rat nervous system. Anat. Embryol. (1999) 199 439-449.
68. DIECK S T, HEUER H, EHRCHEN J, OTTO C, BAUER K: The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative β-Ala-Lys-Nepsilon-AMCA in astrocytes. Glia (1999) 25:10-20.
69. GRONEBERG DA, RUBIO-ALIAGA I, NICKOLAUS M, DORING F, DANIEL H: Direct visualization of peptide uptake activity in the central nervous system of the rat. Neurosci. Lett. (2004) 364:32-36.
70. +/peptide transporter PEPT2. Brain Res. (2004) 997:52-61.
71. +/peptide transporter PEPT2 mediated transport system. Neurosci. Lett. (1999) 271:117-120.
72. SMITH DE, JOHANSON CE, KEEP RF: Peptide and peptide analog transport systems at the blood-CSF barrier. Adv. Drug Deliv. Rev. (2004) 56:1765-1791.
73. NEUMANN J, BRANDSCH M: Delta-aminolevulinic acid transport in cancer cells of the human extrahepatic biliary duct. J. Pharmacol. Exp. Ther. (2003) 305:219-224.
74. +-peptide cotransport in the human bile duct epithelium cell line SK-ChA-1. Am. J. Physiol. Gastrointest. Liver Physiol. (2002) 283:G222-G229.
75. MAHESHWARI M, CHRISTIAN S, LIU C et al.: Mutation screening of two candidate genes from 13q32 in families affected with Bipolar disorder: human peptide transporter (SLC15A1) and human glypican5 (GPC5). BMC Genomics (2002) 3:30.
76. PHAN DD, CHIN-HONG P, LIN ET, ERLE P, SADEE W, GUGLIELMO BJ: Intra- and interindividuall variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrob. Agents Chemother. (2003) 47:2351-2353.
77. +/peptide cotransporter 2 causes a complete loss of transport function. Biochem. Biophys. Res. Commun. (2004) 316:416-420.
78. LIU W, LIANG R, RAMAMOORTHY S et al.: Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. Biochim. Biophys. Acta. (1995) 1235:461-466.
79. BOTKA CW, WITTIG TW, GRAUL RC et al. Human proton/oligopeptide transporter (POT) genes: identification of putative genes using bioinformatics. AAPS Pharmsci. (2000) 2:16.
80. DANTZIG AH, HOSKINS JA, TABAS LB, et al.: Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science. (1994) 264:430-433.
81. GONZALEZ DE, COVITZ KM SADEE W, MRSNY RJ: An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res. (1998) 58:519-525.